Literature DB >> 22766408

A poison center's ten-year experience with flumazenil administration to acutely poisoned adults.

Allyson A Kreshak1, F Lee Cantrell, Richard F Clark, Christian A Tomaszewski.   

Abstract

BACKGROUND: The frequency of seizures among acutely poisoned adults who are administered flumazenil has not been well established. STUDY
OBJECTIVE: The objectives of the study were: to determine the frequency of seizures among acutely poisoned adults administered flumazenil; to identify factors associated with seizures; and to determine the mental status of subjects before and after administration of flumazenil.
METHODS: This study was a historical case series of acutely poisoned adults reported to a poison control system from 1999 to 2008. Included cases were those involving administration of flumazenil to subjects who were ≥ 18 years of age. Both genders were included. Variables collected included: presence of seizure or death, exposure to a pro-convulsant drug, and mental status before and after flumazenil administration.
RESULTS: Over the 10-year period studied, 904 cases were identified that met inclusion criteria. Thirteen subjects (1.4%) developed seizures after flumazenil was administered. One death occurred. There were 293 subjects exposed to a pro-convulsant drug, and 8 of these had seizures after flumazenil administration. Development of seizures after flumazenil administration was significantly associated with exposure to a pro-convulsant drug (odds ratio 3.41; 95% confidence interval 1.13-10.72). Mental status before and after flumazenil administration was available for 546 subjects (60.3%). Of these, 291 (53.3%) became awake after administration of flumazenil.
CONCLUSIONS: Flumazenil administration to acutely poisoned adults resulted in a low frequency of seizures and death. Development of seizures was associated with exposure to a pro-convulsant drug. More than half of the subjects for whom mental status was recorded became awake after receiving flumazenil.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766408     DOI: 10.1016/j.jemermed.2012.01.059

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  7 in total

Review 1.  Flumazenil, naloxone and the 'coma cocktail'.

Authors:  Marco L A Sivilotti
Journal:  Br J Clin Pharmacol       Date:  2015-09-21       Impact factor: 4.335

2.  Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center.

Authors:  Philip W Moore; J Ward Donovan; Keith K Burkhart; Jeffrey A Waskin; Michelle A Hieger; Audrey R Adkins; Yijin Wert; David A Haggerty; J J Rasimas
Journal:  J Med Toxicol       Date:  2014-06

Review 3.  Who gets antidotes? choosing the chosen few.

Authors:  Nicholas A Buckley; Andrew H Dawson; David N Juurlink; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2016-02-17       Impact factor: 4.335

4.  Effect of Flumazenil on Hypoactive Delirium in the ICU: A Double-Blind, Placebo-Controlled Pilot Study.

Authors:  Kendra J Schomer; Jeremiah J Duby; Rachelle L Firestone; Erin L Louie; Christian M Sebat; Dawn M Love; Christine S Cocanour; Timothy E Albertson
Journal:  Crit Care Explor       Date:  2020-03-24

5.  Poisoning with Drugs of Abuse: Identification and Management.

Authors:  Lekhansh Shukla; Deepak S Ghadigaonkar; Pratima Murthy
Journal:  Indian J Crit Care Med       Date:  2019-12

6.  Antidotes in Poisoning.

Authors:  Binila Chacko; John V Peter
Journal:  Indian J Crit Care Med       Date:  2019-12

Review 7.  Endotracheal Intubation in the Pharmaceutical-Poisoned Patient: a Narrative Review of the Literature.

Authors:  Glenn A Burket; B Zane Horowitz; Robert G Hendrickson; Gillian A Beauchamp
Journal:  J Med Toxicol       Date:  2020-05-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.